Pacific Biosciences of California, Inc. (PACB)
$
1.18
+0.04 (3.39%)
Key metrics
Financial statements
Free cash flow per share
-0.7500
Market cap
372.3 Million
Price to sales ratio
2.4174
Debt to equity
1.1206
Current ratio
13.0992
Income quality
0.6650
Average inventory
62.2 Million
ROE
-0.5705
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Pacific Biosciences of California, Inc. specializes in designing, developing, and manufacturing sequencing systems aimed at unraveling genetically complex challenges. The gross profit ratio is 0.24 reflecting the efficiency of the company’s production and sales operations. The net total of other income and expenses is $48,046,000.00 shedding light on the company’s non-core financial activities. The EBITDA is -$356,381,000.00 a key indicator of the company's operational profitability, illustrating its performance in generating earnings. Furthermore, the weighted average number of shares outstanding is 274,488,000.00 highlighting the company's shareholder base. The company's stock is identified with the symbol 'PACB' in the market, making it easier for investors to track its performance. Pacific Biosciences offers a variety of products, including PacBio's Systems that conduct, monitor, and analyze biochemical sequencing reactions, along with consumables like single molecule real-time (SMRT) cells and reagent kits tailored for specific workflows. Their market outreach extends to research institutions, clinical laboratories, genome centers, and pharmaceutical companies, among others. The stock is affordable at $1.15 suitable for budget-conscious investors looking for opportunities in the market. With a high average trading volume of 11,371,001.00 the stock indicates strong liquidity, allowing for easier buying and selling. With a market capitalization of $351,465,360.00 the company is classified as a small-cap player, positioning it uniquely within the industry landscape. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape and driving innovation forward. Additionally, it belongs to the Healthcare sector, where its advancements foster growth and enhance competitive dynamics. The company also maintains a development and commercialization agreement with Invitae Corporation, further expanding its market presence.
What is Pacific Biosciences of California, Inc. (PACB)'s stock forecast?
Analysts predict Pacific Biosciences of California, Inc. stock to fluctuate between $1.08 (low) and $3.70 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Pacific Biosciences of California, Inc.'s market capitalization?
As of 2025-04-01, Pacific Biosciences of California, Inc.'s market cap is $351,465,360, based on 297,852,000 outstanding shares.
How does Pacific Biosciences of California, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Pacific Biosciences of California, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Pacific Biosciences of California, Inc. (PACB) stock?
To buy Pacific Biosciences of California, Inc. (PACB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PACB. Place an order (Market, Limit, etc.).
What is the best time to invest in Pacific Biosciences of California, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Pacific Biosciences of California, Inc. perform in the last earnings report?
Revenue: $154,014,000 | EPS: -$1.13 | Growth: -6.61%.
Where can I find Pacific Biosciences of California, Inc.'s investor relations reports?
Visit https://www.pacb.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Pacific Biosciences of California, Inc.?
You can explore historical data from here
What is the all-time high and low for Pacific Biosciences of California, Inc. stock?
All-time high: $53.69 (2021-02-11) | All-time low: $1.08 (2025-03-31).
What are the key trends affecting Pacific Biosciences of California, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
marketwatch.com
Pacific Biosciences of California has hired Jim Gibson as its new chief financial officer, effective March 31.
zacks.com
Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close.
zacks.com
PACB continues to deliver growth from its unique technologies amid macroeconomic concerns.
globenewswire.com
MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes.
zacks.com
In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.22, denoting a +1.67% change from the preceding trading day.
seekingalpha.com
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock
globenewswire.com
MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 400,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on February 10, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
seekingalpha.com
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - President and CEO Michele Farmer - Chief Accounting Officer Conference Call Participants Tycho Peterson - Jefferies Kyle Mikson - Canaccord Dan Brennan - TD Cowen Doug Schenkel - Wolfe Research Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Sung Ji Nam - Scotia Bank Mason Carrico - Stephens Operator Good day. And welcome to the PacBio Fourth Quarter 2024 Earnings Conference Call.
zacks.com
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.
See all news
